CVE:EPI - ESSA Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$4.65 +0.10 (+2.20 %)
(As of 05/21/2018 01:32 AM ET)
Previous CloseC$4.65
Today's RangeC$4.31 - C$4.65
52-Week RangeC$3.01 - C$7.15
Volume1,300 shs
Average Volume16,587 shs
Market CapitalizationC$7.70 million
P/E RatioN/A
Dividend Yield0.83%

About ESSA Pharma (CVE:EPI)

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Receive EPI News and Ratings via Email

Sign-up to receive the latest news and ratings for EPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-189.16%


Outstanding Shares5,776,000

ESSA Pharma (CVE:EPI) Frequently Asked Questions

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the Canadian Venture Exchange (CVE) under the ticker symbol "EPI."

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for ESSA Pharma.

Who are some of ESSA Pharma's key competitors?

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the folowing people:
  • Dr. David Ross Parkinson, Pres, CEO & Director (Age 68)
  • Mr. David S. Wood, CFO & Principal Accounting Officer (Age 61)
  • Mr. Peter A. Virsik, Exec. VP & COO (Age 47)
  • Dr. Raymond Andersen, CTO, Sec. & Director (Age 71)
  • Dr. Marianne D. Sadar, Chief Scientific Officer & Director (Age 57)

Has ESSA Pharma been receiving favorable news coverage?

Press coverage about EPI stock has been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ESSA Pharma earned a daily sentiment score of 0.10 on Accern's scale. They also gave news articles about the company an impact score of 46.39 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of ESSA Pharma?

Shares of EPI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is ESSA Pharma's stock price today?

One share of EPI stock can currently be purchased for approximately C$4.65.

How big of a company is ESSA Pharma?

ESSA Pharma has a market capitalization of C$7.70 million.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 Broadway W Suite 720, VANCOUVER, BC V5Z 1K5, Canada. The company can be reached via phone at +1-778-3310962.

MarketBeat Community Rating for ESSA Pharma (EPI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  14 (Vote Underperform)
Total Votes:  26
MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe EPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ESSA Pharma (CVE:EPI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for ESSA Pharma in the last 12 months. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

ESSA Pharma (CVE:EPI) Consensus Price Target History

Price Target History for ESSA Pharma (CVE:EPI)

ESSA Pharma (CVE:EPI) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
3/26/2018HC WainwrightReiterated RatingBuyView Rating Details
1/18/2018Bloom BurtonUpgradeHold ➝ BuyView Rating Details
(Data available from 5/21/2016 forward)


ESSA Pharma (CVE:EPI) Earnings History and Estimates Chart

Earnings by Quarter for ESSA Pharma (CVE:EPI)

ESSA Pharma (CVE EPI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018Q1 2018C($0.09)ViewN/AView Earnings Details
12/11/2017Q4 2017C($0.11)ViewN/AView Earnings Details
8/14/2017Q3 2017C($0.23)C($0.22)ViewN/AView Earnings Details
5/15/2017Q2 2017C($0.34)ViewN/AView Earnings Details
2/13/2017Q1 2017C$0.07ViewN/AView Earnings Details
12/14/2016Q4 2016C($0.20)ViewN/AView Earnings Details
8/12/2016Q3 2016C($0.17)ViewN/AView Earnings Details
5/13/2016Q2 2016C($0.27)ViewN/AView Earnings Details
2/12/2016Q1 2016C($0.17)C($0.23)ViewN/AView Earnings Details
12/14/2015Q4 2015C($0.07)C$0.03ViewN/AView Earnings Details
8/17/2015Q3 2015C($0.13)C($0.35)ViewN/AView Earnings Details
5/28/2015Q2 2015C($0.22)C($0.21)ViewN/AView Earnings Details
2/27/2015Q1 2015C($0.10)ViewN/AView Earnings Details
1/26/2015Q4 2014C($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


ESSA Pharma (CVE:EPI) Dividend Information

ESSA Pharma pays an annual dividend of C$0.22 per share, with a dividend yield of 4.73%.
Annual Dividend:$0.22
Dividend Yield:4.73%
Payout Ratio(s):N/A
Dividend Payments by Quarter for ESSA Pharma (CVE:EPI)

ESSA Pharma (CVE:EPI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ESSA Pharma (CVE EPI) Insider Trading and Institutional Ownership History

Insider Trading History for ESSA Pharma (CVE:EPI)

ESSA Pharma (CVE EPI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


ESSA Pharma (CVE EPI) News Headlines

ESSA Pharma consolidating shares to meet Nasdaq requirementsESSA Pharma consolidating shares to meet Nasdaq requirements - April 19 at 9:30 PM
HC Wainwright Reaffirms "Buy" Rating for ESSA Pharma (EPI)HC Wainwright Reaffirms "Buy" Rating for ESSA Pharma (EPI) - March 29 at 12:23 PM
Brokers Issue Forecasts for ESSA Pharma Incs FY2018 Earnings (EPI)Brokers Issue Forecasts for ESSA Pharma Inc's FY2018 Earnings (EPI) - February 23 at 12:12 PM
ESSA Pharma (EPI) Stock Rating Upgraded by Bloom BurtonESSA Pharma (EPI) Stock Rating Upgraded by Bloom Burton - January 20 at 6:30 AM

SEC Filings

ESSA Pharma (CVE:EPI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


ESSA Pharma (CVE EPI) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.